StockData
MapLight Therapeutics, Inc. logo

MapLight Therapeutics, Inc. (MPLT) stock

MPLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$6.57−0.33 (-4.78%)

Close on Nov 17, 2026Market cap $304.70MP/E –Yield –

Earnings

MapLight Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Dec 3, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q1 FY2026
–
EPS, Q1 FY2026
-$1.34
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of MapLight Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Dec 3, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 13, 2026after the close–––Release
Q1 FY2026ended Mar 31, 2026May 14, 2026after the close––-$1.34Release
Q4 FY2025ended Dec 31, 2025Mar 26, 2026before the open––-$2.47Release
Q3 FY2025ended Sep 30, 2025Dec 4, 2025before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

MapLight Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When MapLight Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases MapLight Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Update
  7. Update
  8. Update
  9. Update
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?